Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EP Vantage MedTech Half-Year Review 2014


EP Vantage MedTech Half-Year Review 2014

 Download EP Vantage MedTech Half-Year Review 2014

EP Vantage MedTech Half-Year Review 2014, based on EvaluateMedTech market intelligence, provides an overview of the medical device and diagnostic sector's performance in the first half of 2014.

The sun is finally shining on the medtech industry: after a shocking year in which mergers, funding and FDA approvals all slipped badly, the sector is seeing improvements across the board. 

Key highlights in EP Vantage's MedTech Half-Year Review 2014 include:
  • The combined value of acquisitions reached $27.2 billion during the first half of the year, surpassing the full-year total of 2013 by more than 40%
  • Second quarter venture capital deals rose 33% over the first quarter, exceeding the billion-dollar mark for the first time since the second quarter of 2013
  • The FDA awarded 17 first-time PMAs in the first half of 2014, nearly double the nine awarded in the first half 2013. Moreover, the devices have been assessed almost twice as fast as the same period last year

Download Report

Press Release

Download EP Vantage Pharma and Biotech Half Year Report 2014

Related Reports: 

EP Vantage Job Numbers Report

EP Vantage Medtech 2013 in Review

EP Vantage Pharma and Biotech 2013 in Review

EP Vantage: A Breakthrough Year for Unmet Diseases

EP Vantage FDA Approval Rates 2013